Precision Business Insights
Portfolio

 

Research Reports

Global Ovarian Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Ovarian Cancer Treatment Market

 

Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in woman. Thereby need for development of the more effective drugs in treatment of ovarian cancer.

 

Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the ovarian cancer treatment market.

 

Ovarian cancer treatment market segmented on the basis of type of cancer, drug class, and stage

 

Based on type of cancer, ovarian cancer treatment market is segmented into

  • Epithelial Ovarian Tumor
  • Ovarian Germ Cell Tumor
  • Ovarian Stomatal Tumor
  • Primary Peritoneal Carcinoma

 

Based on drug class, ovarian cancer treatment market is segmented into

  • Chemotherapeutic Agents
  • Targeted Therapy Drugs
  • Immune System Modulators
  • Hormones

 

Based on distribution channel, ovarian cancer treatment market is segmented into

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

 

Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.

 

Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.

 

Some of the players in ovarian cancer treatment market include Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novogen Limited (Australia) , Aeterna Zentaris Inc. (U.S)., GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany) and F. Hoffmann-La Roche AG (Switzerland) to name a few.

 

  • In December 2016 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation

 

Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  1. Executive summary
  2. Global Ovarian Cancer Treatment Market Introduction
    • Global Ovarian Cancer Treatment Market– Taxonomy
    • Global Ovarian Cancer Treatment Market–Definitions
      • Drug Class
      • Cancer Type
  1. Global Ovarian Cancer Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Ovarian Cancer Treatment Market Dynamics – Factors Impact Analysis
    • Global Ovarian Cancer Treatment Market– Regulations
      • S
      • Europe
      • Japan
    • Global Ovarian Cancer Treatment Market– Recent Product Launches
  2. Global Ovarian Cancer Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Ovarian Cancer Treatment Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024
    • Chemotherapeutic Agents
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Targeted Therapy Drugs
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Immune System Modulators
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Hormones
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Ovarian Cancer Treatment Market Forecast, By Cancer Type, 2013 – 2017 and Forecast, 2018 – 2024
    • Epithelial Ovarian Tumor
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Ovarian Germ Cell Tumor
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Ovarian Stomatal Tumor
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Ovarian Cancer Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Ovarian Cancer Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Ovarian Cancer Treatment Market- Opportunity Analysis Index – By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2018 – 2024
  2. North America Ovarian Cancer Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapeutic Agents
      • Targeted Therapy Drugs
      • Immune System Modulators
      • Hormones
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Epithelial Ovarian Tumor
      • Ovarian Germ Cell Tumor
      • Ovarian Stomatal Tumor
      • Primary Peritoneal Carcinoma
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Ovarian Cancer Treatment Market- Opportunity Analysis Index – By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • North America Ovarian Cancer Treatment Market Dynamics – Trends
  3. Europe Ovarian Cancer Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapeutic Agents
      • Targeted Therapy Drugs
      • Immune System Modulators
      • Hormones
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Epithelial Ovarian Tumor
      • Ovarian Germ Cell Tumor
      • Ovarian Stomatal Tumor
      • Primary Peritoneal Carcinoma
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Ovarian Cancer Treatment Market- Opportunity Analysis Index – By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • Europe Ovarian Cancer Treatment Market Dynamics – Trends
  4. Asia-Pacific Ovarian Cancer Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapeutic Agents
      • Targeted Therapy Drugs
      • Immune System Modulators
      • Hormones
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Epithelial Ovarian Tumor
      • Ovarian Germ Cell Tumor
      • Ovarian Stomatal Tumor
      • Primary Peritoneal Carcinoma
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Ovarian Cancer Treatment Market- Opportunity Analysis Index – By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
  • Asia-Pacific Ovarian Cancer Treatment Market Dynamics – Trends
  1. Latin America Ovarian Cancer Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapeutic Agents
      • Targeted Therapy Drugs
      • Immune System Modulators
      • Hormones
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Epithelial Ovarian Tumor
      • Ovarian Germ Cell Tumor
      • Ovarian Stomatal Tumor
      • Primary Peritoneal Carcinoma
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Ovarian Cancer Treatment Market- Opportunity Analysis Index – By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • Latin America Ovarian Cancer Treatment Market Dynamics – Trends
  2. Middle East & Africa Ovarian Cancer Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Chemotherapeutic Agents
      • Targeted Therapy Drugs
      • Immune System Modulators
      • Hormones
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Epithelial Ovarian Tumor
      • Ovarian Germ Cell Tumor
      • Ovarian Stomatal Tumor
      • Primary Peritoneal Carcinoma
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Ovarian Cancer Treatment Market- Opportunity Analysis Index – By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • MEA Ovarian Cancer Treatment Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Eli Lilly and Company (U.S.)
      • Johnson & Johnson Services, Inc. (U.S.)
      • Novogen Limited (Australia)
      • Aeterna Zentaris Inc. (U.S)
      • GlaxoSmithKline plc (UK)
      • Boehringer Ingelheim GmbH (Germany
      • Hoffmann-La Roche AG (Switzerland)
  1. Research Methodology
  2. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR

CALL US ON : 123456789

<p style=”text-align: center;”><strong></strong></p><p style=”text-align: center;”> </p>

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials

Contact SalesTOLL FREE: +1-866-598-1553